Should We Still Believe in Randomized Controlled Trials in Nephrology

Monica Cortinovis, Norberto Perico, Giuseppe Remuzzi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The randomized controlled trial (RCT) is the cornerstone upon which clinical decision-making is based. Pivotal RCTs in the nephrology area efficiently demonstrated the renoprotective effects of treatment with renin-angiotensin system inhibitors in patients with diabetic and non-diabetic proteinuric nephropathies. However, there is concern about the increasing cost, complexity and duration of clinical studies. Moreover, recent large RCTs addressing key issues for patients with renal disease failed to achieve definitive conclusions mainly due to critical flaws in the investigational strategies, including the adoption of excessive/fixed doses of the study medications, inappropriate use of the placebo-controlled design, enrollment of low-risk individuals, poor reporting of adverse events or unreliable evaluation of renal function. The information now available on the biases that characterize the current RCTs should serve as a tool to rethink the design, patient selection and implementation of future RCTs in nephrology.

Original languageEnglish
JournalNephron
DOIs
Publication statusAccepted/In press - Sep 20 2016

Fingerprint

Nephrology
Randomized Controlled Trials
Kidney
Renin-Angiotensin System
Patient Selection
Placebos
Costs and Cost Analysis
Therapeutics
Clinical Decision-Making
Clinical Studies

Keywords

  • Nephrology
  • Randomized double-blind trial
  • Renal diseases

ASJC Scopus subject areas

  • Physiology
  • Nephrology
  • Urology
  • Physiology (medical)

Cite this

Should We Still Believe in Randomized Controlled Trials in Nephrology. / Cortinovis, Monica; Perico, Norberto; Remuzzi, Giuseppe.

In: Nephron, 20.09.2016.

Research output: Contribution to journalArticle

@article{c6372dd832974519ba52d020062c15c9,
title = "Should We Still Believe in Randomized Controlled Trials in Nephrology",
abstract = "The randomized controlled trial (RCT) is the cornerstone upon which clinical decision-making is based. Pivotal RCTs in the nephrology area efficiently demonstrated the renoprotective effects of treatment with renin-angiotensin system inhibitors in patients with diabetic and non-diabetic proteinuric nephropathies. However, there is concern about the increasing cost, complexity and duration of clinical studies. Moreover, recent large RCTs addressing key issues for patients with renal disease failed to achieve definitive conclusions mainly due to critical flaws in the investigational strategies, including the adoption of excessive/fixed doses of the study medications, inappropriate use of the placebo-controlled design, enrollment of low-risk individuals, poor reporting of adverse events or unreliable evaluation of renal function. The information now available on the biases that characterize the current RCTs should serve as a tool to rethink the design, patient selection and implementation of future RCTs in nephrology.",
keywords = "Nephrology, Randomized double-blind trial, Renal diseases",
author = "Monica Cortinovis and Norberto Perico and Giuseppe Remuzzi",
year = "2016",
month = "9",
day = "20",
doi = "10.1159/000450618",
language = "English",
journal = "Experimental Nephrology",
issn = "0028-2766",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Should We Still Believe in Randomized Controlled Trials in Nephrology

AU - Cortinovis, Monica

AU - Perico, Norberto

AU - Remuzzi, Giuseppe

PY - 2016/9/20

Y1 - 2016/9/20

N2 - The randomized controlled trial (RCT) is the cornerstone upon which clinical decision-making is based. Pivotal RCTs in the nephrology area efficiently demonstrated the renoprotective effects of treatment with renin-angiotensin system inhibitors in patients with diabetic and non-diabetic proteinuric nephropathies. However, there is concern about the increasing cost, complexity and duration of clinical studies. Moreover, recent large RCTs addressing key issues for patients with renal disease failed to achieve definitive conclusions mainly due to critical flaws in the investigational strategies, including the adoption of excessive/fixed doses of the study medications, inappropriate use of the placebo-controlled design, enrollment of low-risk individuals, poor reporting of adverse events or unreliable evaluation of renal function. The information now available on the biases that characterize the current RCTs should serve as a tool to rethink the design, patient selection and implementation of future RCTs in nephrology.

AB - The randomized controlled trial (RCT) is the cornerstone upon which clinical decision-making is based. Pivotal RCTs in the nephrology area efficiently demonstrated the renoprotective effects of treatment with renin-angiotensin system inhibitors in patients with diabetic and non-diabetic proteinuric nephropathies. However, there is concern about the increasing cost, complexity and duration of clinical studies. Moreover, recent large RCTs addressing key issues for patients with renal disease failed to achieve definitive conclusions mainly due to critical flaws in the investigational strategies, including the adoption of excessive/fixed doses of the study medications, inappropriate use of the placebo-controlled design, enrollment of low-risk individuals, poor reporting of adverse events or unreliable evaluation of renal function. The information now available on the biases that characterize the current RCTs should serve as a tool to rethink the design, patient selection and implementation of future RCTs in nephrology.

KW - Nephrology

KW - Randomized double-blind trial

KW - Renal diseases

UR - http://www.scopus.com/inward/record.url?scp=84988600933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988600933&partnerID=8YFLogxK

U2 - 10.1159/000450618

DO - 10.1159/000450618

M3 - Article

JO - Experimental Nephrology

JF - Experimental Nephrology

SN - 0028-2766

ER -